𝛼SK or Search

ENTITY

3D Medicines (1244 HK)

24

Analysis

Health Care • China

3D Medicines Inc. operates as a commercial-stage biopharmaceutical company. The Company focuses on the development of differentiated immuno-oncology drugs. 3D Medicines conducts businesses in China.

more

Refresh

Exchange Announcement • 27 May 2026 08:03

Voluntary Announcement Phase Iii Study Results Of Envafolimab Plus Gemox In First-Line Treatment Of Advanced Biliary Tract Cancer To Be Officially Presented At 2026 Asco Annual Meeting

Exchange Announcement • 21 May 2026 20:40

Voluntary Announcement Early Completion Of Enrollment In The Phase Iii Clinical Trial Of Envafolimab For Neoadjuvant/Adjuvant Treatment Of Non-Small Cell Lung Cancer

Exchange Announcement • 30 Apr 2026 16:33

Annual Report 2025

Exchange Announcement • 01 Apr 2026 12:26

Discloseable Transaction; And Clarification Announcement On The Annual Results Announcement For The Year Ended December 31, 2025

Exchange Announcement • 31 Mar 2026 22:47

Annual Results Announcement For The Year Ended December 31, 2025

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.69.1

x